Companies: 10,795·Total market cap: $144.5T
Janux Therapeutics, Inc.

Janux Therapeutics, Inc.

JANXNASDAQHealthcare● Active
$13.62
+$0.26(+1.95%)
Market Cap$830606901
P/E Ratio
52W High$35.34
52W Low$12.12
Overview

Janux Therapeutics, Inc. (JANX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · JANX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.84janx eps ttm · janx earnings per shareEarnings history
PE Ratio (TTM)janx pe ratio ttm · janx price to earningsPE Ratio deep dive
Revenue (TTM)$21.6Mjanx revenue ttm · janx annual revenueFull revenue history
Dividend YieldNo Dividenddoes janx pay dividends · janx dividend yieldDividend history
Shares Outstanding62.0Mjanx shares outstanding · janx floatShares outstanding history
Next EarningsAug 6, 2026Est.janx earnings date · janx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$10.0M▼ 5.55% YoY
202320242025
janux therapeutics, inc. revenue · janx revenue 2025
FY 2025Net Income-$113.6M▼ 64.69% YoY
202320242025
janux therapeutics, inc. net income · janx profit 2025
FY 2025EPS$-1.83▼ 42.97% YoY
202320242025
janx eps · janux therapeutics, inc. earnings per share 2025
TTM:Revenue: $21.6MNet Income: -$114.5MEPS: $-1.84View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy15 analystsis janx a buy · janx analyst rating
Strong Buy
0
Buy
11
Hold
3
Sell
1
Strong Sell
0
12-Month Price Target
$14.00Low
$13.62Current
$23.40Avg Target71.81% upside
$36.00High
janx price target · janx 12 month forecast

Total: 15 · Buy rate: 73.3%

The JANX analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month price target is $23.40, representing +71.81% upside from the current price of $13.62.

Stock Performance

Full History
1D+1.65%
1W-0.51%
1M-4.23%
3M-1.88%
YTD-1.59%
1Y-47.65%
5Y-46.00%

About Janux Therapeutics, Inc.

CEODavid Alan Campbell
IPO DateJun 11, 2021
Employees91
CountryUS

Janux Therapeutics, Inc. a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. T…

what is janux therapeutics, inc. · janx stock overview · janux therapeutics, inc. company profile · who is janux therapeutics, inc. ceo · janx NASDAQ · janux therapeutics, inc. headquarters · janux therapeutics, inc. business segments

About Stock Overview & Key Data

Janux Therapeutics, Inc. (JANX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 11, 2021. As of the latest trading session, JANX stock price is $13.62, with a market capitalization of $830.9M. The stock has returned -47.65% over the past 12 months and -1.59% year-to-date.

According to 15 Wall Street analysts, the consensus rating for Janux Therapeutics, Inc. stock is Buy, with an average 12-month price target of $23.40. In fiscal year 2025, Janux Therapeutics, Inc. reported revenue of $10.0M and net income of -$113.6M. For detailed data — including Janux Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Janux Therapeutics, Inc. (JANX) stock price is $13.62. The stock is traded on NASDAQ under the ticker symbol JANX. The 52-week range is $12.12 – $35.34.

JANX stock priceJANX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice